Citizens JMP Reiterates a Buy Rating on CorMedix Inc. (CRMD)

CorMedix Inc. (NASDAQ:CRMD) is one of the best affordable biotech stocks to invest in now. On September 9, Citizens JMP analyst Jason Butler reiterated a Buy rating on CorMedix Inc. (NASDAQ:CRMD) and set a price target of $22.00.

In other news, CorMedix Inc. (NASDAQ:CRMD) announced on September 2 the successful completion of its previously announced acquisition of Melinta Therapeutics LLC. Melinta Therapeutics LLC is a private commercial-stage company that provides innovative therapies for acute and life-threatening illnesses.

Management called the deal “transformational” for the company, expanding and diversifying its commercial product portfolio with “seven innovative drug products and a pipeline expansion indication with near–term revenue growth potential”.

CorMedix Inc. (NASDAQ:CRMD) is a medical device and biopharmaceutical company that develops and commercializes therapeutics to treat and prevent diseases and medical conditions.

While we acknowledge the potential of CRMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.